Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.

Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S.

Cell Rep. 2018 Apr 17;23(3):918-929. doi: 10.1016/j.celrep.2018.03.093.

2.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators.

Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.

3.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

4.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

5.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

6.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815.

7.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

8.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A.

Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.

9.

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, Brennan T, Zanghi J, Halenbeck R, Marshall SA, Qin M, Doberstein SK, Hollenbaugh D, Kavanaugh WM, Williams LT, Baker KP.

Sci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.

10.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
11.

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.

Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC.

Cancer Immunol Immunother. 2010 Sep;59(9):1313-23. doi: 10.1007/s00262-010-0858-5. Epub 2010 May 25.

PMID:
20499060
12.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

13.

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Fang J, Yi S, Simmons A, Tu GH, Nguyen M, Harding TC, VanRoey M, Jooss K.

Mol Ther. 2007 Jun;15(6):1153-9. Epub 2007 Mar 20.

14.

Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer.

Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, Jooss KU, Harding TC.

Mol Ther. 2007 May;15(5):912-20. Epub 2007 Jan 23.

15.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

16.

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.

Harding TC, Dickinson PJ, Roberts BN, Yendluri S, Gonzalez-Edick M, Lecouteur RA, Jooss KU.

Hum Gene Ther. 2006 Aug;17(8):807-20.

PMID:
16942441
17.

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma.

Harding TC, Lalani AS, Roberts BN, Yendluri S, Luan B, Koprivnikar KE, Gonzalez-Edick M, Huan-Tu G, Musterer R, VanRoey MJ, Ozawa T, LeCouter RA, Deen D, Dickinson PJ, Jooss K.

Mol Ther. 2006 May;13(5):956-66. Epub 2006 Mar 31.

18.

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.

Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K.

Cancer Res. 2005 Aug 1;65(15):6901-9.

19.

Stable antibody expression at therapeutic levels using the 2A peptide.

Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K.

Nat Biotechnol. 2005 May;23(5):584-90. Epub 2005 Apr 17.

PMID:
15834403
20.

Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors.

Farson D, Harding TC, Tao L, Liu J, Powell S, Vimal V, Yendluri S, Koprivnikar K, Ho K, Twitty C, Husak P, Lin A, Snyder RO, Donahue BA.

J Gene Med. 2004 Dec;6(12):1369-81.

PMID:
15538729
21.

Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.

Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, Nichols TC, Bellinger DA, Yendluri S, Waugh J, McArthur J, Veres G, Donahue BA.

Gene Ther. 2004 Jan;11(2):204-13.

PMID:
14712305
22.

Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used.

Glover CP, Bienemann AS, Hopton M, Harding TC, Kew JN, Uney JB.

J Gene Med. 2003 Jul;5(7):554-9.

PMID:
12825194
23.

Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size.

Yang GS, Schmidt M, Yan Z, Lindbloom JD, Harding TC, Donahue BA, Engelhardt JF, Kotin R, Davidson BL.

J Virol. 2002 Aug;76(15):7651-60.

24.

Inhibition of JNK by overexpression of the JNL binding domain of JIP-1 prevents apoptosis in sympathetic neurons.

Harding TC, Xue L, Bienemann A, Haywood D, Dickens M, Tolkovsky AM, Uney JB.

J Biol Chem. 2001 Feb 16;276(7):4531-4. Epub 2000 Dec 19.

25.

Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors.

Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB.

Neuroreport. 2000 Jun 26;11(9):2051-5.

PMID:
10884069
26.

Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells.

Maile R, Elsegood KA, Harding TC, Uney JB, Stewart CE, Banting G, Dayan CM.

Immunology. 2000 Mar;99(3):367-74.

27.

Assessing viral gene therapy in neuroendocrine models.

Geddes BJ, Harding TC, Lightman SL, Uney JB.

Front Neuroendocrinol. 1999 Oct;20(4):296-316. Review.

PMID:
10569280
28.

Overexpression of hsp70i facilitates reactivation of intracellular proteins in neurones and protects them from denaturing stress.

Beaucamp N, Harding TC, Geddes BJ, Williams J, Uney JB.

FEBS Lett. 1998 Dec 18;441(2):215-9.

29.

Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system.

Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB.

Nat Biotechnol. 1998 Jun;16(6):553-5.

PMID:
9624686
30.

Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors.

Harding TC, Geddes BJ, Noel JD, Murphy D, Uney JB.

J Neurochem. 1997 Dec;69(6):2620-3.

32.

Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: suppression of the immune response with cyclosporin.

Geddes BJ, Harding TC, Hughes DS, Byrnes AP, Lightman SL, Conde G, Uney JB.

Endocrinology. 1996 Nov;137(11):5166-9.

PMID:
8895393

Supplemental Content

Loading ...
Support Center